American Society of Clinical Oncology (ASCO)

Watch Matthew Lunning, DO, FACP, discuss the latest frontline advances in high-risk, newly diagnosed DLBCL, presented at the 2026 ASCO Annual Meeting. In this video, Dr. Lunning reviews the phase 3 frontMIND trial with progression-free survival and safety outcomes for tafasitamab plus lenalidomide in combination with R-CHOP. Read More ›

A wave of emerging therapies, from chemotherapy-free bispecific antibodies to targeted molecular strategies, is expanding treatment options and personalizing care for patients with DLBCL across diverse clinical settings. Read More ›

Real-world data show bispecific antibodies offer an alternative to CAR-T therapy in B-cell lymphomas. Emerging differences between agents like glofitamab and epcoritamab may influence treatment choice. Read More ›

Emerging evidence in DLBCL highlights how improved surveillance tools, evolving prognostic factors, and intensified frontline strategies are converging to enable more precise, risk-adapted patient management. Read More ›

Emerging advances in molecular profiling, imaging-based risk assessment, and survivorship research are redefining how clinicians stratify risk, tailor treatment, and manage long-term outcomes in DLBCL. Read More ›

Older age may not limit CAR-T success in DLBCL, but across subtypes, factors like HIV status, comorbidities, and treatment access remain key drivers of patient survival. Read More ›

Tislelizumab and pemetrexed achieve a durable response rate with manageable toxicity, potentially offering a promising new option for patients with primary DLBCL of the CNS. Read More ›

R-miniCVP delivers high response rates with manageable toxicity in unfit/frail, older patients with newly diagnosed DLBCL. Read More ›

A targeted BTK inhibitor added to standard R-da-EPOCH shows promising efficacy and manageable safety in patients with HIV-associated DLBCL. Read More ›

Golcadomide plus Pola-R-CHP shows promising deep and durable responses with high MRD negativity in newly diagnosed, high-risk, aggressive B-cell lymphoma. Read More ›